Pietrzak I, Czarnecki R, Baczyk K, Młynarczyk M, Kaczmarek M
Klinika Nefrologii, Instytutu Chorób Wewnetrznych, Akademii Medycznej im. K. Marcinkowskiego w Poznaniu.
Przegl Lek. 2000;57(7-8):369-73.
The depressed ETKA in ESRD patients is supposed to be caused and/or aggravated by several factors among which the diminished content of thiamine in blood and/or disturbances of thiamine utilization seem to play the major role. This role stems from the fact that thiamine acts as the cofactor of transketolase. In order to check the therapeutic significance of this relationship we introduced the thiamine pyrophosphoric acid ester chloride (Cocarboxylasum-CC) administration in 25 patients (mHD + CC). Immediately after each HD performance CC was given i.v. during 12 weeks in a doses of 5 mg/kg b.w., 3 times a week. The blood for ETKA value, free and total thiamine in plasma and erythrocytes, as well as, the total protein and albumins/globulins index investigation was drawn before, after 6 and 12 weeks of CC administration, and 3 months after cessation of this therapy. In 10 patients, on maintenance HD nontreated by CC (mHD), the blood was drawn at the same time intervals. Normal values we obtained from 15 healthy volunteers. For ETKA evaluation photocolorimetric method was used, thiamine content in blood was estimated by fluorimetric method. At the beginning of the study the mean value of ETKA, in two examined groups, was found statistically decreased (p < 0.01) when compared with normals. Mean values of thiamine in plasma and erythrocytes were lower but did not differ significantly from those in normals. After 6 weeks of CC administration ETKA value increased, but only after 12 weeks it increased significantly (p < 0.01), reaching normal value. On the other hand, striking increase in plasma thiamine and erythrocyte thiamine levels was observed after 6 weeks of CC administration already (p < 0.01). Three months after cessation of CC administration significant decrease in ETKA value and thiamine level in blood was observed (p < 0.01). ETKA returned to lower value than in normals even in the presence of still high thiamine levels in blood. In mHD patients nontreated by CC the ETKA value and thiamine levels in blood did not change significantly during all periods of study. The nutritional status assessed by total protein and albumins/globulins index did not change in both groups through the study. We conclude, the administration of high doses of CC to ESRD patients on maintenance hemodialysis HD was successful in terms of increasing ETKA value and thiamine levels in blood without any side effects. Thus, supplementation with large doses of CC deserves further study because it promises to be another adjunct in the treatment of potential thiamine deficiency and metabolic disturbances in the course of dialysotherapy.
终末期肾病(ESRD)患者中红细胞转酮醇酶活性(ETKA)降低被认为是由多种因素引起和/或加重的,其中血液中硫胺素含量降低和/或硫胺素利用障碍似乎起主要作用。这一作用源于硫胺素作为转酮醇酶的辅酶这一事实。为了检验这种关系的治疗意义,我们对25例患者(维持性血液透析+CC)给予了氯硫胺素焦磷酸酯(Cocarboxylasum - CC)。每次血液透析结束后立即静脉注射CC,持续12周,剂量为5mg/kg体重,每周3次。在给予CC前、给药6周和12周后以及停止治疗3个月后采集血液,用于检测ETKA值、血浆和红细胞中游离及总硫胺素,以及总蛋白和白蛋白/球蛋白指数。在10例未接受CC治疗的维持性血液透析(mHD)患者中,在相同时间间隔采集血液。从15名健康志愿者获得正常值。采用光比色法评估ETKA,用荧光法测定血液中硫胺素含量。研究开始时,与正常人相比,两个检测组的ETKA平均值在统计学上显著降低(p<0.01)。血浆和红细胞中硫胺素的平均值较低,但与正常人相比无显著差异。给予CC 6周后ETKA值升高,但仅在12周后才显著升高(p<0.01),达到正常值。另一方面,给予CC 6周后血浆硫胺素和红细胞硫胺素水平就已显著升高(p<0.01)。停止给予CC 3个月后,观察到ETKA值和血液中硫胺素水平显著降低(p<0.01)。即使血液中硫胺素水平仍然较高,ETKA也恢复到低于正常人的值。在未接受CC治疗的mHD患者中,整个研究期间ETKA值和血液中硫胺素水平无显著变化。通过总蛋白和白蛋白/球蛋白指数评估的营养状况在两组研究过程中均未改变。我们得出结论,在维持性血液透析的ESRD患者中给予高剂量CC成功提高了ETKA值和血液中硫胺素水平,且无任何副作用。因此,大剂量CC补充值得进一步研究,因为它有望成为透析治疗过程中潜在硫胺素缺乏和代谢紊乱治疗的另一种辅助手段。